Skip to main content
. 2020 Mar 27;323(16):1565–1573. doi: 10.1001/jama.2020.3308

Figure 2. Kaplan-Meier Estimate of Time to First Occurrence of the Primary Efficacy End Point.

Figure 2.

The primary end point was time to cardiovascular death or nonfatal myocardial infarction or stroke. Median observation time for the apabetalone group was 781 days (interquartile range [IQR], 566-967) and for the placebo group, 772 days (IQR, 560-960).